Sanyou Bio conducted a full review of its Intelligent Super-trillion Molecule Discovery Platform. As the core technology of the platform, the intelligent super-trillion molecule library boasts a ...

Discover how next-generation kinase inhibitors are transforming clinical therapy byovercoming resistance and enhancing ...

Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical ...

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and ...

Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel ...

Using an approach called DNA origami, scientists at Caltech have developed a technique that could lead to cheaper, reusable ...

FoRx Therapeutics appoints Dr. Jens Wurthner, PhD, as Chief Medical Officer and reports progress toward IND submission by mid ...

Avidity Biosciences specializes in RNA-based therapies using Antibody-oligonucleotide conjugates to deliver drugs directly to ...

February 20, 2025, Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery ...

By registering with CLIA, Avance Biosciences asserts that it has established the necessary infrastructure and quality systems to meet rigorous quality standards and federal regulatory requirements for ...

Rather, TIL have made a decisive move toward an in-licensing strategy, bringing in a bispecific antibody called SYN-2510.

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and ...